Pamorelin LA 11.25

Pamorelin LA is a medication used to treat certain types of cancer, including prostate cancer, breast cancer, and lung cancer. It is an injectable medication that works by reducing the production of hormones that stimulate the growth of cancer cells.

Composition:

Pamorelin LA contains Triptorelin, a medication that is a synthetic gonadotropin-releasing hormone (GnRH) agonist.

Indications:

Pamorelin LA is indicated for the treatment of:

1. Prostate cancer in patients with advanced disease
2. Breast cancer in patients with advanced disease
3. Lung cancer in patients with advanced disease
4. Other types of cancer, including ovarian and pancreatic cancer

Mechanism of Action:

Triptorelin works by:

1. Activating the GnRH receptor, which stimulates the release of gonadotropin-releasing hormone (GnRH)
2. Suppressing the production of gonadotropins, which are hormones that stimulate the production of estrogen and testosterone
3. Reducing the production of estrogen and testosterone, which are hormones that stimulate the growth of cancer cells

Dosage and Administration:

The recommended dosage of Pamorelin LA is:

• 11.25mg administered as an intramuscular injection every 4 weeks
• The dose should be administered by a healthcare professional

Side Effects:

Common side effects of Pamorelin LA include:

1. Hot flashes
2. Flushing
3. Headache
4. Nausea and vomiting
5. Diarrhea
6. Abdominal pain
7. Injection site reactions

Serious side effects can include:

1. Allergic reactions
2. Severe allergic reactions
3. Blood clots
4. Infections
5. Respiratory problems

Contraindications:

Pamorelin LA is contraindicated in patients with:

1. Hypersensitivity to Triptorelin or other GnRH agonists
2. Severe liver or kidney disease
3. Pregnancy or breastfeeding
4. History of angioedema or other allergic reactions

Precautions:

1. Patients with a history of hypertension or edema should be closely monitored while receiving Pamorelin LA.
2. Patients with a history of liver disease should be closely monitored while receiving Pamorelin LA.
3. Patients with a history of respiratory disease should be closely monitored while receiving Pamorelin LA.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of hot flashes or other side effects.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.